| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.028 | 0.6 |
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | indisulam | CTRPv2 | pan-cancer | AAC | 0.019 | 0.6 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | 0.095 | 0.6 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |